YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
* Sutro Biopharma press release [https://seekingalpha.com/pr/20616182-sutro-biopharma-reports-second-quarter-2026-financial-results-and-provides-early-update-on] (STRO [https://seekingalpha.com/symbol/STRO]): Q2 GAAP EPS of -$2.33 misses b…
Key Points Reduced stake by 140,000 shares; estimated transaction value of $4.11 million based on quarterly average price Quarter-end position value fell by $5.18 million, reflecting both trading and stock price changes Post-trade holding:…
MannKind (MNKD) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items. This qua…
Sutro Biopharma, Inc. (NASDAQ:STRO) is one of the best performing small cap stocks so far in 2026. Citizens lifted the price target on Sutro Biopharma, Inc. (NASDAQ:STRO) to $41 from $35 on April 23, reaffirming an Outperform rating on the…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Summit Insights upgraded Qualcomm (QCOM) t…
Quick Read As expected, the Federal Reserve did not lower rates at its meeting, which is likely the last time we will see Jay Powell as Chairman. The Chairman said he expects the first-quarter gross domestic product to take a hit from the…
Sutro Biopharma Inc. (NASDAQ:STRO) is one of the tiny stocks that are on fire right now. On March 23, Sutro Biopharma reported its full-year 2025 financial results, highlighting a strengthened balance sheet and significant clinical milesto…
STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs STRO-006 and STRO-227 show meaningful, dose-dependent antitumor activity acro…
Sutro Biopharma, Inc. (STRO) shares soared 7.4% in the last trading session to close at $25.71. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 4.1% loss over t…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Rosenblatt upgraded Arista Networks (ANET)…
Vaxcyte (PCVX) is a clinical-stage vaccine innovation company focused on developing next-generation vaccines to protect people from serious bacterial infectious diseases. While Vaxcyte is still a clinical-stage company, Wall Street seems h…
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today…
Sutro Biopharma, Inc. (STRO) shares rallied 5.9% in the last trading session to close at $15.8. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the sto…
Sutro Biopharma, Inc. SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug con…
– Initial clinical data expected mid-2026 – SOUTH SAN FRANCISCO, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-fo…
- Company has initiated Phase 1 study with STRO-004, its potential best-in-class Tissue Factor ADC - - Sutro has selected PTK7 as the target for its initial dual-payload candidate, STRO-227 - - Investor webcast today at 7:00AM PT / 10:00AM…
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.59 per share a year ago. These figures are adjusted for non-recurring item…
– Company announces U.S. FDA clearance of Investigational New Drug (IND) application for STRO-004, its potential best-in-class Tissue Factor ADC; Expects to dose first patient before year-end – – Company presented new preclinical data at W…
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that…
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its…
* Sutro Biopharma (NASDAQ:STRO [https://seekingalpha.com/symbol/STRO]) announced [https://seekingalpha.com/pr/20248029-sutro-biopharma-announces-operational-restructuring-intended-to-extend-cash-runway-through] on Monday an organizational…
– Extends cash runway into at least mid-2027 – SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antib…
* Sutro Biopharma press release [https://seekingalpha.com/pr/20194321-sutro-biopharma-reports-second-quarter-2025-financial-results-and-business-highlights] (NASDAQ:STRO [https://seekingalpha.com/symbol/STRO]): Q2 GAAP EPS of -$0.14. * Rev…
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.59 per share a year ago. These figures are adjusted for non-recurring item…
Cytokinetics (CYTK) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $1.34. This compares to a loss of $1.31 per share a year ago. These figures are adjusted for non-recurring items. This q…
SUTRO BIOPHARMA INC (NASDAQ:STRO [https://www.chartmill.com/stock/quote/STRO]) reported its second-quarter 2025 financial results, delivering a significant revenue beat while narrowing its losses compared to analyst expectations. The compa…
– On track to initiate FIH study with STRO-004, potential best-in-class Tissue Factor ADC, in the second half of 2025 – – Expanded breadth of preclinical data across pipeline, including STRO-006 and dual-payload ADCs – – Entered research c…
As the European market navigates a landscape marked by tentative optimism surrounding potential EU-U.S. trade agreements, indices like the STOXX Europe 600 have experienced modest gains, reflecting cautious investor sentiment amid ongoing…
As European markets experience tentative optimism amid potential trade agreements with the U.S., the pan-European STOXX Europe 600 Index has seen a modest rise. In this environment, identifying stocks that may be trading below their estima…
Strongpoint ASA reported strong financial results for the second quarter of 2025, showcasing significant improvements in revenue and profitability. The company achieved an 18% year-over-year revenue increase, reaching NOK 350 million. EBIT…
Introduction & Market Context StrongPoint ASA (OB:STRO) presented its second quarter 2025 results on July 11, showing continued revenue growth and improved profitability as the retail technology provider expands its footprint across Europe…
Piper Sandler upgraded Sutro Biopharma (NASDAQ:STRO) from Neutral to Overweight on Monday, setting a price target of $2.00 for the biopharmaceutical company focused on antibody-drug conjugates (ADCs). According to InvestingPro data, the st…
- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization - - Promising preclinical results with STRO-004 and dual-payload ADC, as well as STRO-006 programs presented…
SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced pos…
Enable social media cookies to share Which stocks are moving on Monday? By Mill Chart Last update: Apr 7, 2025 Here are the top movers in Monday's session, showcasing the stocks with significant price changes. Today's top gainers TickerCha…
Enable social media cookies to share Keep an eye on the top gainers and losers in Monday's session. By Mill Chart Last update: Apr 7, 2025 Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top ga…